Skip to Content

IDEXX Laboratories Inc IDXX

Morningstar Rating
$509.82 +9.00 (1.80%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Idexx Earnings: Soft Clinical Vet Visits Hamper Growth

Narrow-moat Idexx delivered soft first-quarter results that led management to adjust the outlook downward. However, our estimates remain bounded by the revised guidance, albeit on the high end of the range now, and we’re leaving our fair value estimate unchanged. Though the firm kept a tight rein on expenses, quarterly top-line growth of 7% slightly lagged the high-single-digit pace that Idexx usually delivers. Management indicated severe weather in the first quarter likely depressed revenue growth by 50 to 100 basis points. Nonetheless, even after adjusting for weather patterns, sales growth was still on the anemic side.

Price vs Fair Value

IDXX is trading at a 890% premium.
Price
$509.82
Fair Value
$869.00
Uncertainty
Medium
1-Star Price
$998.00
5-Star Price
$679.00
Economic Moat
Bmzhvqq
Capital Allocation
Bwbtfldwj

Bulls Say, Bears Say

Bulls

Unlike human healthcare, pet health services and products require cash payments—thereby bypassing the reimbursement issues and pricing pressure associated with third-party payers.

Bears

International sales account for a substantial chunk of Idexx's total revenue; as the U.S. dollar strengthens, Idexx would feel the pain on its top and bottom lines.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IDXX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$500.82
Day Range
$501.68510.62
52-Week Range
$372.50583.39
Bid/Ask
$480.00 / $560.00
Market Cap
$42.10 Bil
Volume/Avg
526,504 / 426,275

Key Statistics

Price/Earnings (Normalized)
49.74
Price/Sales
11.49
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.52%

Company Profile

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Growth
Total Number of Employees
11,000

Competitors

Valuation

Metric
IDXX
ZTS
Price/Earnings (Normalized)
49.7431.36
Price/Book Value
27.0215.27
Price/Sales
11.498.92
Price/Cash Flow
42.6327.08
Price/Earnings
IDXX
ZTS

Financial Strength

Metric
IDXX
ZTS
Quick Ratio
1.021.71
Current Ratio
1.573.33
Interest Coverage
30.6813.06
Quick Ratio
IDXX
ZTS

Profitability

Metric
IDXX
ZTS
Return on Assets (Normalized)
29.78%17.68%
Return on Equity (Normalized)
73.17%51.21%
Return on Invested Capital (Normalized)
38.93%22.36%
Return on Assets
IDXX
ZTS
See how this stock stacks up to its competitors with Morningstar Investor

Diagnostics & Research Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
TMO
Thermo Fisher Scientific IncQtgvjhzmJzbb$220.6 Bil
DHR
Danaher CorpHqjqdrnyMytjr$184.8 Bil
A
Agilent Technologies IncFjxbmwcsbTgk$43.9 Bil
IQV
IQVIA Holdings IncDkxjryfVxljbxp$42.6 Bil
MTD
Mettler-Toledo International IncBqyjrrrtkmMgppxq$32.3 Bil
ICLR
Icon PLCNdltwnllvJhssxn$26.1 Bil
WAT
Waters CorpRxxrqgbjDvyk$20.8 Bil
ILMN
Illumina IncJpjpjqsyJxhhbt$17.6 Bil
LH
Laboratory Corp of America HoldingsSwjrwrqphCdnqkm$17.4 Bil

Sponsor Center